Compare IPHA & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | FT |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 202.6M |
| IPO Year | 2019 | N/A |
| Metric | IPHA | FT |
|---|---|---|
| Price | $1.85 | $7.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 21.7K | ★ 63.0K |
| Earning Date | 09-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,839,695.00 | N/A |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $5.97 |
| 52 Week High | $3.51 | $7.23 |
| Indicator | IPHA | FT |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 40.17 |
| Support Level | $1.85 | $7.84 |
| Resistance Level | $1.91 | $7.99 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.63 | 15.63 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.